Ace Therapeutics is an expert in the field of liver disease drug development. We promote progress in the field of liver disease research by identifying potential liver disease therapeutic targets, providing a wealth of research ideas, and quality research services.
Liver fibrosis is an important cause of high morbidity and mortality in patients with liver disease. Interventional treatment of liver disease can be effectively carried out by timely curbing the progression of liver fibrosis. Based on our advanced research platform and expertise, we offer a range of liver disease drug development services for liver fibrosis.
What Can We Do?
In general, drug development for antifibrosis in liver disease consists of 2 main areas, namely hepatocyte protection and inhibition of hepatic stellate cell (HSC) activation and fibrosis. We provide scientific and comprehensive research services for the development of anti-fibrotic liver disease drugs to facilitate the discovery of anti-fibrotic drugs.
- Anti-fibrotic Drug Development Targets Hepatocyte Protection
Given that hepatocyte death is a major trigger for inflammation and HSC activation during the evolution of liver fibrosis, we provide a comprehensive research service targeting the development of drugs that protect hepatocytes for effective mitigation of liver fibrosis.
- Cell apoptosis inhibitors screening
For hepatocyte death caused by apoptosis, we will screen extensively for inhibitors of apoptotic pathways by targeting pan-caspase, ASK, and other targets using high-throughput screening methods.
- Oxidative stress inhibitors screening
For hepatocyte death caused by oxidative stress, we will screen for effective hepatic fibrosis regulators to inhibit hepatocyte damage due to oxidative stress, such as the MAPK signaling pathway and NOX enzymes in liver fibrosis.
- HSC Activity Inhibitors Development for Liver Disease
Activation, proliferation, and transformation of HSC are important aspects of liver fibrosis. Therefore, inhibiting the progression of liver fibrosis by starting with hepatic stellate cells is an effective therapeutic target. We offer a comprehensive research service to explore HSC activity inhibitors with therapeutic effects on liver disease.
- Analyze differential targets with biochip technology
We will comprehensively screen the pathways and other mechanisms of action that inhibit HSC activity by gene chip technology and protein microarray technology.
Based on our ultra-large compound library, we will customize the screening of suitable HSC activity inhibitors for you.
Our Preclinical Activity Evaluation Services Include
- Construction of different experimental models for liver disease
- Comprehensive evaluation of liver injury
- Biomarkers detection
Ace Therapeutics has extensive research experience in the field of liver disease drug development. Based on our professional technology and well-developed research platform, we will customize a scientific service plan for you. If you would like to learn more about our services, please feel free to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
